Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10126109 | 0.80 | MAPT (0.50) | MAPTGSK3BALDH1A1KMT2AHTT | |
| SCHEMBL5034243 | 0.80 | MAPT (0.46) | MAPTGSK3BALDH1A1KMT2AHTT | |
| SCHEMBL5868892 | 0.78 | GAA (0.46) | MAPTGSK3BALDH1A1KMT2AHTT | |
| Hydrochloric Acid SCHEMBL4941652 | 0.78 | MAPT (0.45) | MAPTGSK3BALDH1A1KMT2AHTT | |
| SCHEMBL2775083 | 0.78 | GSK3B (0.57) | GSK3BALDH1A1GAAPTPN1 | |
| SCHEMBL155500 | 0.77 | — | — | |
| SCHEMBL5569894 | 0.76 | GSK3B (0.67) | GSK3BKMT2AGAAPKM | |
| SCHEMBL18901337 | 0.76 | GAA (0.44) | MAPTGSK3BALDH1A1KMT2AHTT | |
| SCHEMBL17790208 | 0.76 | MAPT (0.50) | MAPTGSK3BALDH1A1KMT2AHTT | |
| SCHEMBL4337185 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358962-B2 | 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-10975073-B2 | Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190048003-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190048002-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-10138234-B2 | 2-phenyl or 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2018-11-27 | — | — | US | disclosed |
| EP-2991983-B1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-A]PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-20160244441-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-2758380-B1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | disclosed |
| EP-2265606-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-10-21 | — | — | EP | disclosed |
| US-9073881-B2 | Benzoic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-7435750-B2 | Method of using substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435750-B2 | Method of using substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435750-B2 | Method of using substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| WO-2007117180-A1 | AZAHETEROCYCLES, COMBINATORY LIBRARY, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE PRODUCTION THEREOF | 'CHEMICAL DIVERSITY RESEARCH INSTITUTE' LTD. (RU) | 2007-10-18 | — | — | WO | disclosed |
| US-7041685-B2 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| WO-2006012577-A2 | QUINAZOLINONE DERIVATIVES USEFUL FOR THE REGULATION OF GLUCOSE HOMEOSTASIS AND FOOD INTAKE | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1406632-A2 | SUBSTITUTED 3-ARYL-5-ARYL- 1,2,4]-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2002100826-A2 | SUBSTITUTED 3-ARYL-5-ARYL-[1,2,4]-OXADIAZOLES AND ANALOGS | CYTOVIA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048003-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HTR3D, GDI2, GDI1 | MAPT 1018/4885GSK3B 4403/4885ALDH1A1 2878/4885 |
| US-10975073-B2 | Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives | HTR3D, PTGDR2, PTGIR | MAPT 2831/4885GSK3B 4244/4885ALDH1A1 2980/4885 |
| US-10138234-B2 | 2-phenyl or 2-hetaryl imidazol[1,2-a]pyridine derivatives | CNKSR1, HCAR3, HCAR1 | MAPT 4305/4885GSK3B 4112/4885ALDH1A1 128/4885 |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, API5 | MAPT 4724/4885GSK3B 432/4885ALDH1A1 136/4885 |
| US-20160244441-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HTT, HCAR2, HCAR3 | MAPT 8/4885GSK3B 3680/4885ALDH1A1 3066/4885 |
| US-20190048002-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HTR3D, GDI2, GDI1 | MAPT 1018/4885GSK3B 4403/4885ALDH1A1 2878/4885 |
| US-11358962-B2 | 2-hetaryl imidazol[1,2-a]pyridine derivatives | TBXA2R, HRH2, CYP4F3 | MAPT 3434/4885GSK3B 4628/4885ALDH1A1 873/4885 |
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, CASP4 | MAPT 4660/4885GSK3B 469/4885ALDH1A1 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.